Therapeutic agent for rheumatoid arthritis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 14, 2013
Grant Date -
Feb 18, 2010
app pub date -
Oct 18, 2007
filing date -
Oct 20, 2006
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
When C60 was added to synovial fibroblasts, infiltrating lymphocytes, and macrophages, and the inflammatory cytokine production level was measured, the inflammatory cytokine production level was significantly suppressed in all cells. Furthermore, when C60 was added to osteoclast precursor cells and cultured in the presence of osteoclast differentiation-inducing factors, a certain concentration or more of C60 suppressed their differentiation into osteoclasts. Observation of the effect of C60 addition on bone resorption showed that C60 suppressed bone resorption by osteoclasts. In addition, the use of arthritis model animals confirmed in vivo that C60 suppressed inflammatory symptoms, as well as bone resorption and bone destruction by osteoclasts. C60 is effective for treating arthritic diseases such as rheumatoid arthritis through its effects of suppressing osteoclast differentiation, bone resorption, and inflammatory cytokines.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully